^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PF-06671008
i
Other names: PF-06671008, PF-6671008, PF 6671008
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Pfizer
Drug class:
CD3 agonist, CDH3 inhibitor
Related drugs:
almost2years
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. (PubMed, Front Immunol)
Cytokine peak concentrations and CRS grade appeared to positively correlate with C. Although the study was terminated due to limited antitumor activity, it provides important insights into understanding and managing immune-related adverse events resulting from this class of molecules. URL: https://clinicaltrials.gov/ct2/show/NCT02659631, ClinicalTrials.gov Identifier: NCT02659631.
P1 data • Clinical Trial,Phase I • Journal
|
CDH3 (Cadherin 3)
|
PF-06671008
Share via
